Paysign (PAYS)

A major part of Paysign’s business is tied to healthcare and pharmaceutical payment solutions. The company offers patient affordability programs that can help eligible patients access prescribed therapies by reducing out-of-pocket costs or simplifying reimbursement and claims-related payment flows. These services are used by pharmaceutical and healthcare clients seeking compliant, trackable, and efficient ways to administer financial support programs.

Beyond healthcare, Paysign also serves industries such as hospitality, retail, and other commercial markets that require prepaid cards or managed payment programs. Its platform can support use cases including incentives, disbursements, payroll-adjacent payments, and other stored-value or transaction-based solutions. The company earns revenue from a mix of sources, including cardholder-related fees, interchange, program management fees, transaction and claims processing fees, and settlement income.

Paysign’s appeal lies in its ability to combine payments infrastructure with tailored program management. Rather than offering only generic card issuing, it works with clients to design payment products around specific business needs and regulatory requirements. As a public company, Paysign gives investors exposure to niche areas of the payments market, especially healthcare-focused financial technology. Its performance is influenced by client adoption, transaction volumes, program renewals, compliance demands, and the broader shift toward digital and card-based disbursement systems.